
Isomorphic Labs Funding Reaches $5B to Advance AI-Designed Drugs
Alphabet-backed Isomorphic Labs has raised $5 billion in Series C funding co-led by Greenoaks and Sequoia Capital. The AI drug developer plans to advance its oncology and immunology candidates toward clinical trials while expanding its drug-design technology.










